Table 4 Univariate and multivariate Cox regression analysis of the EV 3-mRNA prognostic signature in the combined training and validation cohort

Age

 ≤ 65y/ > 65y

N = 174

0.78

0.54–1.14

0.204

–

–

–

Gender

Female/Male

N = 174

0.79

0.55–1.15

0.226

–

–

–

Stage

I-II/III-IV

N = 172

1.59

1.09–2.32

0.017

1.25

0.81–1.92

0.320

Grade

 G1–2/G3–4

N = 146

1.22

0.81–1.85

0.346

–

–

–

Resections

 R0/R1

 R0/R2

N = 168

1.11

3.23

0.74–1.67

1.67–6.24

0.618

 < 0.001

1.08

3.11

0.71–1.63

1.41–6.87

0.735

0.005

Neoadjuvant chemotherapy

 No/yes

N = 107

0.78

0.43–1.41

0.407

–

–

–

Adjuvant chemotherapy

 No/yes

N = 113

0.76

0.37–1.56

0.458

–

–

–

Risk score

 Low/high

N = 174

1.57

1.06–2.32

0.024

1.57

1.03–2.39

0.035